کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8673343 | 1578839 | 2018 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Proton Pump Inhibitors: Review of Emerging Concerns
ترجمه فارسی عنوان
مهار کننده های پمپ پروتون: بررسی مشکالت ناگهانی
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
FDACDIRDANSAIDSIBOPPIBMDAKIacute kidney injury - آسیب حاد کلیهchronic kidney disease - بیماری مزمن کلیویBone mineral density - تراکم معدنی استخوانRelative risk - خطر نسبیnonsteroidal anti-inflammatory drug - داروهای ضد التهابی غیر استروئیدیRecommended dietary allowance - رژیم غذایی پیشنهادیFood and Drug Administration - سازمان غذا و داروClostridium difficile infection - عفونت کلستریدیوم دیفیسیلProton pump inhibitor - مهار کننده پمپ پروتونCKD - نارسایی مزمن کلیهodds ratio - نسبت شانس هاCommunity-acquired pneumonia - پنومونی به دست آمده در جامعهCaP - کلاه لبه دار
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
چکیده انگلیسی
First introduced in 1989, proton pump inhibitors (PPIs) are among the most widely utilized medications worldwide, both in the ambulatory and inpatient clinical settings. The PPIs are currently approved by the US Food and Drug Administration for the management of a variety of gastrointestinal disorders including symptomatic peptic ulcer disease, gastroesophageal reflux disease, and nonulcer dyspepsia as well as for prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. PPIs inhibit gastric acid secretion, and the most commonly associated adverse effects include abdominal pain, diarrhea, and headache. Although PPIs have had an encouraging safety profile, recent studies regarding the long-term use of PPI medications have noted potential adverse effects, including risk of fractures, pneumonia, Clostridium difficile diarrhea, hypomagnesemia, vitamin B12 deficiency, chronic kidney disease, and dementia. These emerging data have led to subsequent investigations to assess these potential risks in patients receiving long-term PPI therapy. However, most of the published evidence is inadequate to establish a definite association between PPI use and the risk for development of serious adverse effects. Hence, when clinically indicated, PPIs can be prescribed at the lowest effective dose for symptom control.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings - Volume 93, Issue 2, February 2018, Pages 240-246
Journal: Mayo Clinic Proceedings - Volume 93, Issue 2, February 2018, Pages 240-246
نویسندگان
Avinash K. MD, Jeffrey A. MD, Conor G. MD, Vandana MD,